pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury

BACKGROUND AND OBJECTIVES: The novel coronavirus disease 2019 (COVID-19) has been a pandemic health issue in 30 January 2020. The mortality rate is as high as 50% in critically ill patients. Stem cell therapy is effective for those who are refractory to standard treatments. However, the immune respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mei-Chuan, Lai, Kevin Shu-Leung, Chien, Ko-Ling, Teng, Sing Teck, Lin, Yuh-Rong, Chao, Wei, Lee, Meng-Jung, Wei, Po-Li, Huang, Yen-Hua, Kuo, Han-Pin, Weng, Chih-Ming, Chou, Chun-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109702/
https://www.ncbi.nlm.nih.gov/pubmed/35585988
http://dx.doi.org/10.3389/fimmu.2022.871828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109702/
https://www.ncbi.nlm.nih.gov/pubmed/35585988
http://dx.doi.org/10.3389/fimmu.2022.871828

Ejemplares similares